Skip to main content
OpenTrials
Completed

NCT Number: NCT06659796

LifeVac Survey Study

This observational, non-interventional survey study is intended to explore user experiences with the LifeVac airway clearance device, with a particular emphasis on real-world application in choking emergencies in the USA. This study seeks to gather valuable insights from a representative sample of the LifeVac device purchaser base.

The main questions the study aims to answer are:

1. Is the LifeVac device safe for individuals experiencing a choking emergency? 2. Is the LifeVac device successful in removing an obstruction during a choking incident?

Participants: Purchasers of the LifeVac device.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Boston MedTech Advisors

Dedham, Massachusetts, 02026, United States

About this study

Foreign Body Airway Obstruction (FBAO), commonly referred to as choking, occurs when an aspirated solid or semisolid object becomes lodged in a person's larynx or trachea. If the object is large enough it may cause the complete (or near complete) obstruction of the airway. Without oxygen, brain damage can occur in as soon as four minutes following the event.

LifeVac is a non-powered, non-invasive, single-use airway clearance device developed for resuscitating a victim with an airway obstruction when current choking protocols (basic life support [BLS]) failed to remove the obstruction. The device is intended be used on adults and children, in home and non-home settings, and can be administered by professional/HCP users or laypersons without professional training in a choking emergency.

This observational, non-interventional survey study will be conducted on purchasers of the LifeVac device. The study intends to obtain responses from at least 26 users of the device in each of the two age groups of interest, individuals up to 19 years of age (pediatric) and above 20 years of age (adult), and capture unbiased information on the device users' experience, regardless of its outcome.

Objectives:

  • Gather information on device usage patterns and user experiences with the LifeVac airway clearance device.
  • Collect data on the safety and effectiveness of the device in real-world choking interventions.

Target Population:

Purchasers of the LifeVac device in the USA from 2015 to April 2024.

Data Collection Procedure:

  • Purchasers will be invited to participate via a standardized email with a link to an online platform (IntelliSurvey, Inc.) independent of the device manufacturer.
  • Participation will require electronic consent before accessing the survey.
  • The survey is accessible through a web browser and can be completed on a desktop computer or mobile device.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Purchases of the LifeVac device Original database: all purchasers of the LifeVac device from the LifeVac website starting in 2015 until April 2024, a timeframe that yields a database of above 450,000 individuals with no email duplications and third party suppliers.

Survey batches: randomly selected sample of 50,000 purchasers (10% of the database).

Number of batches required will be based on response rate.

  • English speaking
  • Ability to understand and accept the consent form

Exclusion criteria

  • Did not purchase a LifeVac device
  • Third party suppliers
  • Non-English speakers (as LifeVac labeling and survey materials are only available in English)
  • Unwilling or unable to accept the consent form

Treatment and study plan

LifeVac

Device

Removal of airway obstruction during choking emergency

Primary outcomes

  1. Primary Safety Endpoint

    Time frame: Up to 1 week

    Occurrence of any serious adverse events (SAE) associated with the use of the LifeVac device.

  2. Primary Effectiveness Endpoint

    Time frame: Up to 1 week

    Confirm success or partial success in relieving airway obstruction in at least 80% of uses of the device.

Secondary outcomes

  1. Secondary Safety Endpoint

    Time frame: Up to 1 week

    Occurrence of any adverse events (AE) associated with the use of the LifeVac device.

  2. Secondary Effectiveness Endpoint

    Time frame: Up to 1 week

    Explore potential correlations between the outcome of the device use with age of the choking person, the nature of the obstruction, and the environment where the choking incident transpired.

Sponsors and collaborators

Lead sponsor

LifeVac, LLC

Industry

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 26, 2024
Registry last updated
Jul 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.